Caplyta (lumateperone) is a small molecule pharmaceutical. Lumateperone was first approved as Caplyta on 2019-12-20. It is used to treat schizophrenia in the USA. It is known to target 5-hydroxytryptamine receptor 2A, sodium-dependent serotonin transporter, and D(2) dopamine receptor. Caplyta's patents are valid until 2039-08-30 (FDA).
|Drug Class||Antianxiety agents/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)|